• RIN3–BIN1 Binding and Endosomal Pathology in AD

  2026-10-09

  A 2026 Science Advances study links impaired RIN3–BIN1 binding to RAB5 hyperactivation, enlarged neuronal endosomes, and Alzheimer’s disease–relevant transcriptional changes. By combining mouse genetics with edited human iPSC-derived neurons, the work strengthens the case that BIN1 regulates RIN3-dependent endosomal homeostasis, while also defining important limits for therapeutic interpretation.

• SB 431542: Reframing ALK5 Research for Translation

  2026-10-09

  SB 431542 is more than a pathway inhibitor: it is a mechanistic probe for separating ALK5-dependent TGF-β biology from broader receptor-family and inflammatory effects. This article examines how its reported selectivity, Smad2-centered pharmacology, glioma findings, and immunology applications can be interpreted alongside new evidence on PHF2-driven neuroinflammation—while defining the limits of current translational evidence.

• 4-Phenylbutyric Acid in ER Stress Research

  2026-10-08

  A source-grounded overview of 4-Phenylbutyric acid and 4-PBA as research tools for interpreting ER stress, autophagy, and cell-death mechanisms, with emphasis on published findings, evidence strength, provenance, and applicability limits.

• Super-Enhancer Hijacking in Early Lung Adenocarcinoma

  2026-10-08

  Zhang et al. identify LINC01977 as a super-enhancer-associated long noncoding RNA that links tumor-associated macrophage signaling to the canonical TGF-β/SMAD3 pathway in early-stage lung adenocarcinoma. The study provides a mechanistic framework for understanding how enhancer dysregulation, transcriptional coactivator recruitment, and tumor microenvironment signals may jointly promote relapse-associated biology.

• Prednisolone and ERAD: Evidence and Research Context

  2026-10-07

  Prednisolone is a synthetic glucocorticoid used to study glucocorticoid receptor signaling, inflammation modulation, and immune-cell responses. A 2026 Cell study describes a distinct targeted protein degradation platform based on desonide-derived ERAD-engaging chimeras; current evidence does not establish Prednisolone as an ERAD warhead or connect it directly to PD-L1 or mutant HTT degradation.

• NF 340: Interpreting P2Y11 Evidence

  2026-10-07

  Explore how the P2Y11 antagonist NF 340 helps interpret the connection between QPRT, purinergic signaling, and breast cancer cell invasiveness. This evidence-focused guide separates reported findings from mechanistic inference and outlines broader implications for immunology research and inflammation pathway modulation.

• Dorsomorphin (Compound C): Evidence and Limits

  2026-10-06

  Dorsomorphin, also called Compound C, is a reversible ATP-competitive AMPK inhibitor with additional BMP-pathway activity. Its dual pharmacology makes it useful for mechanistic research, but cellular findings require careful separation of AMPK-dependent, BMP-dependent, and broader stress-response effects.

• L. plantarum P101 and AMPK in Alcoholic Steatosis

  2026-10-06

  Feng and colleagues linked Lactiplantibacillus plantarum P101 with reduced alcohol-induced hepatic lipid accumulation in mice and used pharmacological AMPK inhibition to test whether AMPK activation was functionally important. By combining liver phenotyping with gut microbiota profiling and serum metabolomics, the study offers a multi-layer view of probiotic action while leaving the microbial and metabolic mediators as hypotheses for further validation.

• Pregnenolone Carbonitrile: From PXR to Translation

  2026-10-05

  A source-grounded perspective on Pregnenolone Carbonitrile as a rodent PXR research tool, linking xenobiotic metabolism, CYP3A biology, liver fibrosis questions, and translational pharmacokinetics while clarifying evidence boundaries.

• SGC-CBP30 and the LUAD Super-Enhancer Question

  2026-10-05

  A translational perspective on how SGC-CBP30 can be used as a mechanistic probe of CREBBP/EP300 bromodomain function in the super-enhancer–TGF-β/SMAD3 circuitry described in early-stage lung adenocarcinoma. The article separates established findings from forward-looking hypotheses and outlines the evidence needed to connect chromatin biology with biomarker development.

• Cyclosporin A: Five Questions on Evidence and Scope

  2026-10-04

  This source-grounded overview explains the canonical principles associated with Cyclosporin A, separates commercial product claims from findings in a supplied neuroscience study, and examines what the evidence can—and cannot—show about T-cell signaling, mitochondrial biology, and cortical inhibitory transmission.

• Cycloastragenol Protects Bone in GIONFH

  2026-10-03

  A 2024 in vivo study links cycloastragenol protection in glucocorticoid-induced osteonecrosis of the femoral head to reduced osteoclast activity, preserved trabecular architecture, fewer empty lacunae, and improved local blood supply. The findings support osteoclast biology as a therapeutic research direction, but the evidence remains preclinical and requires independent and clinical validation.

• Angiotensin (1-7): Applied Research Workflows

  2026-10-02

  Build reproducible cell, receptor-binding, renal, and inflammatory studies around Angiotensin (1-7), a Mas receptor agonist with counter-regulatory activity against angiotensin II. This guide connects practical peptide handling with emerging receptor-binding evidence while separating validated applications from exploratory assay design.

• DMH1: An ALK2 Inhibitor for Organoid Research

  2026-10-01

  DMH1 provides a selective way to interrogate BMP-driven signaling in organoid and cancer workflows without treating general kinase inhibition as the explanation. This practical guide connects pancreatic ductal organoid optimization with NSCLC assays, emphasizing controls, dosing logic, readouts, and troubleshooting.

• CRISPR Screen Reveals Brucella Host-Factor Dependencies

  2026-10-01

  This study used a genome-wide CRISPR knockout screen in human THP-1 macrophages to identify host genes that support Brucella invasion and intracellular persistence. Functional validation highlighted WDR4, ZNF532, MTHFD1, and especially TRAPPC2, linking host trafficking, autophagosome formation, apoptosis, and macrophage viability to infection outcomes.

8455 records 1/564 page Next 12345 下5页 Last page